Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101689 | 1.00 | L3MBTL1 (0.50) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL30605712 | 1.00 | L3MBTL1 (0.50) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL12997622 | 1.00 | L3MBTL1 (0.50) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL102965 | 0.83 | LMNA (0.43) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL102966 | 0.83 | LMNA (0.43) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL23188035 | 0.82 | RAB9A (0.47) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL20099346 | 0.82 | RAB9A (0.47) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL5262402 | 0.82 | RAB9A (0.47) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL5262396 | 0.82 | RAB9A (0.47) | L3MBTL1GAALMNARAB9ANPC1 | |
| SCHEMBL21163486 | 0.79 | GAA (0.41) | L3MBTL1GAALMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PSOMAGEN, INC. (US) | 2022-08-23 | — | — | US | claimed |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MACROGEN INC. (KR) | 2021-05-06 | — | — | US | claimed |
| EP-3668494-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | Psomagen, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| WO-2019036507-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | uBiome, Inc. (US) | 2019-02-21 | — | — | WO | claimed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | claimed |
| US-20140026782-A1 | SILVER INK COMPOSITION | INKTEC CO., LTD. (KR) | 2014-01-30 | — | — | US | claimed |
| US-8486203-B2 | Conversion coating and anodizing sealer with no chromium | METALAST INTERNATIONAL, INC. (US) | 2013-07-16 | — | — | US | claimed |
| WO-2012144847-A2 | SILVER INK COMPOSITION | 주식회사 잉크테크 (KR) | 2012-10-26 | — | — | WO | claimed |
| US-20100314004-A1 | CONVERSION COATING AND ANODIZING SEALER WITH NO CHROMIUM | CHEMEON SURFACE TECHNOLOGY, LLC | 2010-12-16 | — | — | US | claimed |
| US-20070114155-A1 | Hydrotreating and/or hydrocracking catalyst of hydrocarbons and preparation thereof | TOTAL RAFFINAGE FRANCE (FR) | 2007-05-24 | — | — | US | claimed |
| JP-2007501701-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1660232-A1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | Total France (FR) | 2006-05-31 | — | — | EP | claimed |
| WO-2005016518-A1 | HYDROTREATING AND/OR HYDROCRACKING CATALYST OF HYDROCARBONS AND PREPARATION THEREOF | TOTAL FRANCE (FR) | 2005-02-24 | — | — | WO | claimed |
| US-12501540-B2 | Electronic device and manufacturing method thereof | FUJIFILM CORPORATION (JP) | 2025-12-16 | — | — | US | disclosed |
| CN-121011241-A | Efficient serum metabolism fingerprint spectrum for diagnosis and prognosis of orbital lymphoma | 上海交通大学 | 2025-11-25 | — | — | CN | disclosed |
| US-12451440-B2 | Electronic device and manufacturing method thereof | FUJIFILM CORPORATION (JP) | 2025-10-21 | — | — | US | disclosed |
| WO-2000020414-A9 | PIPERIDYLOXADIAZOLES AS DOPAMINE RECEPTOR ANTAGONISTS | COMBICHEM INC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6107313-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | COMBICHEM, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000020414-A1 | PIPERIDYLOXADIAZOLES AS DOPAMINE RECEPTOR ANTAGONISTS | COMBICHEM, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-4142044-A | FLUORESCENT DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PNMT, MAOA, HNMT | L3MBTL1 3873/4885GAA 346/4885LMNA 2593/4885 |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MAOA, PNMT, HNMT | L3MBTL1 4566/4885GAA 179/4885LMNA 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.